BPIQ's Smid-Cap Biopharma 2022 Year in Review

Summary:

• The biotech sector saw many exciting events and readouts in 2022

• While smid-cap biopharmas were down more than 20% during 2022, there were still many companies that saw a positive year

• We are anticipating a very exciting 2023 as well, already with a list of Suspected Movers from BPIQ!

2022 Stock Moves

While 2022 was a hard year for biotech and all sub-categories monitored by BPIQ were down overall in 2022, many smid-cap biopharmas still saw positive years.

See Table 1 for a breakdown of moves in 2022 by sub-category. Smid-cap biopharmas monitored by BPIQ are in a market cap range of $50M to $12.5B. Companies in the BPIQ database and NASH companies were the only sub-categories that did better than XBI in 2022. NASH companies saw a huge resurgence since September 2022. Read our NASH article to learn more about those companies in the spotlight.

Table 1. Moves from smid-cap biopharma companies in 2022 - separated by sub-categories monitored by BPIQ

*Market cap of $50M-$12.5B

Want to get Catalyst Events and stocks to watch sent directly to your inbox each week? sign up for our free weekly newsletter

While sub-categories overall saw a negative year, there were still many big winners in almost every category. See Table 2 for a list of the top 5 "winners" and "losers" in each sub-category along with the 2022 move. Unfortunately, not every category saw 5 "winners" this year, and the gene editing companies didn't have one positive moving company in 2022.

Table 2. Big winners and losers from BPIQ smid-cap biopharma sub-categories in 2022

There were many additional big mover events in 2022, and in Table 3 you will find the top movers from the year, sorted by stock move from the event. While most of these top movers were because of Phase 2 or later data, several updates, initiations, and submissions led to large stock raises as well. Many of the big moves came from companies focused on cancers, Alzheimer's, and NASH. See Table 3 for the year's biggest moves. Note that these stock moves are from the event leading to the move, not the year overall.

Companies that moved most during 2022 include: ZEAL (844%), MDWD (472%), PTN (402%), VRNA (289%), DRRX (249%), MDGL (242%), CABA (144%), and AXSM (104%).

Also see our specialized NASH article HERE and our Alzheimer's article HERE.

Table 3. Top smid-cap biopharma event moves in 2022

2022 was full of many interesting M&A's, especially in the fourth quarter of the year, and we hope to see a similar momentum going into J.P. Morgan starting on Monday (Jan 9). See our M&A post for the biggest acquisitions of the year!

Upcoming 2023 Events

As we have looked back at 2022, we are also highly anticipating many events and readouts coming in 2023. At BPIQ we follow events that we believe will lead to large stock changes - named Suspected Movers. Table 4 shows a list of some of these Suspected Movers for 2023, late stage events that we believe will be important in 2023. NASH readouts are still high on our list of companies to keep an eye on, as well as several big approvals coming. We are also highly anticipating several Alzheimer's disease readouts, especially after the BIIB Lecanemab approval today. Table 4 is not a complete list of our current Suspected Movers list, make sure to check out our Big Movers article for additional info on upcoming readouts.

Table 4. Upcoming 2023 Expected Big Readouts

While there were many disappointments in 2022 in the biotech sector, we are still optimistic about 2023 for smid-cap biopharma companies as we see many important readouts coming this next year! XBI is also at a good price to buy right now, which could help start 2023 off well. XBI is currently at $83.16 (as of January 6, 2023), XBI is considered a good buy in the $70s and the low $80s.

This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.

Article history:

Originally posted 1/6/2023

If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.

Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!

P.S. We are currently running a sale - lock in the price before it's gone

See what our members are saying about us:

Mike from United States

Carl from United States

Essey from Canada

James from United States